drugset / Trial / NCT03929016
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Subjects
RandomizedSequentialQuadruple-blindTreatment
Summary
This study will evaluate how the test medicine DNDI-0690 is taken up and broken down by the body and will also look at the safety and tolerability of the test medicine after a single dose. This is the first time the test medicine DNDI-0690 will be administered to humans.
Timeline
- Start
- 2019-04-04
- Primary completion
- 2019-12-06
- Completion
- 2020-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DNDI-0690 | Small molecule | 10 mg | Oral |
| Subject | DNDI-0690 | Small molecule | 30 mg | Oral |
| Subject | DNDI-0690 | Small molecule | 150 mg | Oral |
| Subject | DNDI-0690 | Small molecule | 400 mg | Oral |
| Subject | DNDI-0690 | Small molecule | 1200 mg | Oral |
| Subject | DNDI-0690 | Small molecule | 3600 mg | Oral |